Overview

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by overall response rates at end of course of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Amphotericin B
Liposomal amphotericin B